Global Peanut Allergy Treatment Market Insights Report 2023
August 29, 2023 08:03 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "Peanut Allergy Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Antihistamines,...
Peanut Allergy Treatment Industry Assessment 2023-2030: Surging Towards $1 Billion with Promising Pipeline Progress
August 29, 2023 05:08 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "Peanut Allergy Treatment Market Size, Share & Trends Analysis Report By Drug Class (Antihistamines, Epinephrine), By Route Of Administration, By...
Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy
July 25, 2023 09:35 ET
|
Intrommune Therapeutics
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Global Allergy Diagnostics Market Report 2023: Featuring BioMerieux, Danaher, HOB Biotech, HYCOR Biomedical and Lincoln Diagnostics Among Others
March 08, 2023 04:08 ET
|
Research and Markets
Dublin, March 08, 2023 (GLOBE NEWSWIRE) -- The "Allergy Diagnostics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
October 26, 2022 09:35 ET
|
Intrommune Therapeutics
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...
Intrommune Expands and Strengthens Senior Leadership Team
September 28, 2022 09:35 ET
|
Intrommune Therapeutics
Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development Appointment of William Berger, MD, MBA as Head of...
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
June 22, 2022 09:31 ET
|
Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
June 01, 2022 13:33 ET
|
Intrommune Therapeutics
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
April 06, 2022 08:30 ET
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board
September 21, 2021 09:30 ET
|
Intrommune Therapeutics
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...